非诺贝特与2型糖尿病患者心力衰竭结局:ACCORD分析
基于ACCORD降脂试验中接受辛伐他汀治疗的2型糖尿病患者,非诺贝特组心力衰竭住院或心血管死亡复合终点发生率为6.9%,安慰剂组为8.3%(HR 0.82,95%CI 0.68-1.00,P=0.048)。该获益主要见于标准降糖策略亚组(HR 0.64,95%CI 0.48-0.85),强化降糖策略亚组未见获益(HR 1.02,95%CI 0.79-1.33,交互作用P=0.017)。
要点
- 非诺贝特降低心衰住院或心血管死亡复合终点(HR 0.82,95%CI 0.68-1.00)。
- 标准降糖策略亚组HR 0.64(95%CI 0.48-0.85),强化降糖亚组HR 1.02(95%CI 0.79-1.33)。
- 非诺贝特可致更多一过性eGFR恶化事件,但延缓长期eGFR下降。
核心结论
- 在接受辛伐他汀治疗的2型糖尿病患者中,非诺贝特降低心衰住院或心血管死亡复合终点,该效应主要见于标准背景降糖治疗的患者。
研究设计与样本
- ACCORD降脂试验的事后分析,纳入接受辛伐他汀的2型糖尿病患者5518例,采用Cox回归分析并以背景降糖策略为分层变量,中位随访4.7年。
主要发现
- 中位年龄62岁,女性占31%,既往心衰病史者占5%。
- 心衰住院或心血管死亡复合终点:非诺贝特组190例(6.9%)vs 安慰剂组228例(8.3%),HR 0.82,95%CI 0.68-1.00,P=0.048。
- 标准降糖策略亚组HR 0.64,95%CI 0.48-0.85;强化降糖策略亚组HR 1.02,95%CI 0.79-1.33;交互作用P=0.017。
- 单纯心衰住院结局呈现相似模式。
- 非诺贝特对血脂的影响未受背景降糖治疗在临床重要程度上的影响;非诺贝特导致更多一过性eGFR恶化事件,但延缓长期eGFR下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis. Fenofibrate may reduce HF events through multiple mechanisms. We sought to study the effect of fenofibrate (vs. placebo) in HF outcomes among patients with T2D receiving simvastatin enrolled in the Action to Control Cardiovascular Risk in Diabetes lipid trial (ACCORD Lipid). RESEARCH DESIGN AND METHODS: We used Cox regression analysis with background glucose-lowering strategy as the stratification variable. The median follow-up was 4.7 years. RESULTS: A total of 5,518 patients were included. Median age was 62 years, and 31% were women. Prior HF history was present in 5% of the patients. The composite outcome of HF hospitalization or cardiovascular death occurred in 190 (6.9%) patients in the fenofibrate group vs. 228 (8.3%) in the placebo group: HR 0.82, 95% CI 0.68-1.00 (P = 0.048). The beneficial effect of fenofibrate to reduce HF hospitalizations or cardiovascular death was present among patients receiving standard glucose-lowering strategy, HR 0.64, 95% CI 0.48-0.85, and not among patients receiving intensive glucose-lowering strategy, HR 1.02, 95% CI 0.79-1.33 (Pinteraction = 0.017). A similar pattern was observed for HF hospitalizations alone. The effect of fenofibrate on blood lipids was not influenced by background glucose-lowering therapy in a clinically important manner. Fenofibrate caused more transient worsening estimated glomerular filtration rate (eGFR) events but slowed long-term eGFR decline. CONCLUSIONS: In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy.
引用
- Ferreira JP, Vasques-Nóvoa F, Ferrão D, et al. Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. Diabetes Care. 2022. PMID: 35320363. doi:10.2337/dc21-1977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。